IIC
MDGL icon

Integrated Investment Consultants’s Madrigal Pharmaceuticals MDGL Stock Holding History

Integrated Investment Consultants’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Hold
568
– – 0.06% 200
2026
Q1 		$297K Buy
568
+1
+0.2% +$478 0.06% 196
2025
Q4 		$330K Hold
567
– – 0.06% 194
2025
Q3 		$260K Buy
+567
New +$212K 0.04% 272
2018
Q2 		– Sell
-57
Closed -$7K – 490
2018
Q1 		$7K Buy
+57
New +$7.04K ﹤0.01% 694

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Integrated Investment Consultants's MDGL Position: Q2 2026 in Review

Integrated Investment Consultants held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 568 shares worth $305K. The position accounts for 0.06% of the portfolio, ranked #200.

Integrated Investment Consultants first reported a position in MDGL in Q1 2018 and has held it in 5 quarters since. The position peaked at $330K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Integrated Investment Consultants held 568 shares of Madrigal Pharmaceuticals worth $305K as of Q2 2026.
  • Integrated Investment Consultants left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.06% of Integrated Investment Consultants's portfolio in Q2 2026, its #200 holding.
  • Integrated Investment Consultants first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 5 quarters since.
  • Integrated Investment Consultants's Madrigal Pharmaceuticals position peaked at $330K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Integrated Investment Consultants's 13F filing for Q2 2026, filed 17 Aug 2026.